MRNS: Total Utang marang Modal Marinus Pharmaceuticals, Inc.

Logo perusahaan publik Marinus Pharmaceuticals, Inc. (MRNS)

Marinus Pharmaceuticals (MRNS) management is currently optimizing expenses and revising its R&D program following ambiguous test results. The company is minimizing risks by developing seizure treatments for various age groups. The price visualization on GURU.Markets, which assists in the basic asset valuation, captures the 0.00 metric, confirming the strategy to expand Ztalmy sales and capture market share in the neuropharmaceuticals sector.

MRNS - Total Utang marang Modal Marinus Pharmaceuticals, Inc. ing rentang 04.07.2022 - 22.02.2025

Rincian metrik lan analitis perusahaan Marinus Pharma (MRNS)

- rega lan prakiraan konsensus rega:
Bagan rega Marinus Pharmaceuticals, Inc.|MRNS - Prakiraan gabungan firma investasi
- informasi kapitalisasi pasar:
Kapitalisasi pasar Marinus Pharmaceuticals|MRNS - Total Nilai Perusahaan
- indikator kapitalisasi buku:
Nilai Akuntansi saben Saham Marinus Pharmaceuticals|MRNS - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku marinuspharma.com|MRNS - Nilai Agregat Aset
- indikator beban kredit lan likuiditas emiten:
Utang marang Ekuitas Marinus Pharmaceuticals|MRNS - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Marinus Pharmaceuticals|MRNS - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Marinus Pharmaceuticals|MRNS - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Marinus Pharmaceuticals|Rasio cepet marinuspharma.com
- statistik bathi lan rasio pasar:
MRNS - Asil keuangan resik
Analisis komprehensif perusahaan:Marinus Pharmaceuticals, Inc., MRNS
Barang utama Marinus Pharmaceuticals

Investors are cautiously assessing the potential of Marinus Pharmaceuticals (MRNS), analyzing the ratio of total liabilities to net assets to determine the degree of financial leverage. This proportion of total debt to equity measures the business's reliance on borrowed funds, which is critical for Marinus Pharmaceuticals, where the need for liquidity for new developments amid unstable growth could amplify stock volatility risks.

Pesaing utama

Utang marang Ekuitas Biogen|Rasio Utang marang Ekuitas NBIX (Neurocrine)|Total Utang marang Modal RGC|AXSM - Utang marang Modal|ACADIA Pharmaceuticals - Rasio Total Utang marang Ekuitas|Total Utang marang Modal xenon-pharma.com XENE|VKTX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi SUPN (Supernus Pharmaceuticals, Inc.)|Catalyst Pharmaceuticals Inc (CPRX) - Utang marang Ekuitas|Utang marang Modal Denali Corp (DNLI)|Utang marang Ekuitas Harmony Biosciences|Rasio Total Utang marang Ekuitas biohavenpharma.com (BHVN)|Total Utang marang Modal AMLX|Total Utang marang Modal Trevi Therapeutics Inc (TRVI)|Utang marang Ekuitas Praxis Medicines PRAX|Rasio Kabeh Utang marang Dana Pribadi AVXL|CeriBell, Inc. - Total Utang marang Modal|Koefisien Total Utang marang Modal Prothena Corporation PLC PRTA|alector.com (ALEC) - Utang marang Ekuitas|Rasio Utang marang Ekuitas ANNX|Rasio Total Utang marang Ekuitas OMER|Total Utang marang Modal Neurogene Therapeutics|Utang marang Ekuitas AC Immune (ACIU)|Koefisien Total Utang marang Modal voyagertherapeutics.com|Neumora Therapeutics, Inc. - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi SCLX|TVGN - Utang marang Ekuitas|Utang Agregat marang Ekuitas ACOG|CGTX: Total Utang marang Modal|inhibikase.com - Rasio Kabeh Utang marang Dana Pribadi|SAVA (Cassava Sciences) - Total Utang marang Modal|Total Utang marang Modal Assertio Therapeutics|Utang marang Ekuitas Coya Therapeutics, Inc. (COYA)|VTGN (vistagen.com) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Ovid Therapeutics OVID|ABOS - Rasio Total Utang marang Ekuitas|CervoMed - Total Utang marang Modal|ATHE - Total Utang marang Modal|CLNN: Total Utang marang Modal|Rasio Total Utang marang Ekuitas PepGen|JUNS (Jupiter Neurosciences Inc) - Total Utang marang Modal|Utang marang Modal relmada.com RLMD|Rasio Total Utang marang Ekuitas ANVS (Annovis Bio)|Total Utang marang Modal gracetx.com (GRCE)|Firefly Neuroscience Inc - Rasio Total Utang marang Ekuitas|Utang Agregat marang Modal KLTO (ANEW Medical)|NeuroSense Therapeutics, Ltd. - Total Utang marang Modal|Koefisien Total Utang marang Modal revivapharma.com RVPH|MTVA: Total Utang marang Modal|Rasio Total Utang marang Ekuitas NeurAxis Inc.|HSDT (Helius Medical Technologies, Inc.) - Total Utang marang Modal|Total Utang marang Modal Passage Bio Corp|Utang marang Ekuitas Neuphoria Therapeutics Inc. (NEUP)|Utang marang Ekuitas NERV (minervaneurosciences.com)|Utang marang Ekuitas Athira Pharma ATHA|Koefisien Total Utang marang Modal Addex Therapeutics Ltd. (ADXN)|ALZN - Utang marang Ekuitas|Cyclerion Therapeutics (CYCN) - Rasio Total Utang marang Ekuitas|protagenic.com (PTIX) - Utang marang Ekuitas|Pasithea Therapeutics Corp. - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Cortigent Inc|Rasio Utang marang Ekuitas ATXI (Avenue Therapeutics Inc.)|Utang marang Ekuitas Brainstorm Cell Therapeutics, Inc. (BCLI)|Koefisien Total Utang marang Modal Cara Therapeutics Inc|Utang marang Ekuitas Chromocell Therapeutics CHRO|ELYM: Rasio Utang marang Ekuitas|Intra-Cellular - Total Utang marang Modal|Utang marang Modal Longboard Pharmaceuticals Inc|NKGN (NKGen) - Rasio Total Utang marang Ekuitas|NeuroBo Pharma (NRBO) - Total Utang marang Modal|Utang marang Ekuitas Sage Therapeutics, Inc.|SNPX: Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Trevena (TRVN)|VIGL - Utang marang Modal|Utang marang Ekuitas Anew Medical WENA|CERE - Rasio Total Utang marang Ekuitas